Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy

Clinical trial NCT03199040 · TERMINATED

Trial details

NCT number: NCT03199040
Sponsor: Washington University School of Medicine
Status: TERMINATED
Phase: Phase 1
Study type: INTERVENTIONAL

Triple Negative Breast Cancer Triple Negative Breast Neoplasms TNBC - Triple-Negative Breast Cancer Triple-negative Breast Carcinoma

Start date: 2019-07-23
Primary completion: 2022-11-21
Enrollment: 18

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.